GT Biopharma Announces First Patient Dosed in Phase I Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies

GT Biopharma, Inc. announced that the first patient was dosed in a Phase I trial evaluating GTB-3650, its second-generation TriKE, for the treatment of relapsed or refractory CD33 expressing hematologic malignancies.